Bernstein Liebhard LLP Investigating Potential Tasigna Lawsuits on Behalf of Individuals Who Allegedly Developed Arteriosclerosis and Associated Complications While Undergoing Leukemia Treatment with This Medication

NEW YORK, Jan. 16, 2018 /PRNewswire/ -- The attorneys at Bernstein Liebhard LLP are now providing free Tasigna lawsuit reviews to individuals who developed arteriosclerosis (hardening of the arteries) and associated complications allegedly related to treatment with this leukemia medication.

"Recent evidence suggests that patients who take Tasigna may be at risk for arteriosclerosis, a dangerous condition caused by the buildup of plaque inside these vital blood vessels. Individuals who developed arteriosclerosis while taking Tasigna may be entitled to compensation for medical bills and other damages incurred as a result of their injuries," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices.

Tasigna and Arteriosclerosis

Tasigna (nilotinib) was approved by the U.S. Food & Drug Administration in 2007 to treat patients suffering from Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML). The medication belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which stop leukemia cells from growing by blocking a protein called Bcr-Abl.

The Canadian label for Tasigna was updated in 2013 to note a potential risk of arteriosclerosis, after a review revealed that 277 reports of the condition had been logged with the Novartis global safety database between January 1^st, 2005 and January 31, 2013. Canadian doctors were advised to closely monitor their Tasigna patients for signs of the life-threatening artery disease.

Complications associated with arteriosclerosis include:

• Coronary heart disease
• Angina
• Carotid artery disease
• Peripheral artery disease (PAD)
• Chronic kidney disease
• Amputations
• Heart attack
• Stroke
• Death

Tasigna Lawsuits

In March 2016, a Tasigna lawsuit was filed in the U.S. District Court, Eastern District of California, on behalf of a man who died from complications related to arteriosclerosis shortly after he began taking the drug in 2012. According to the complaint, the Decedent was diagnosed with peripheral artery disease – a symptom of arteriosclerosis – in September 2013, with 90-100% blockages in his legs. Though his doctor switched his treatment after reading a medical journal article linking Tasigna to arteriosclerosis, the patient died from complications in March 2014.

Among other things, the Tasigna lawsuit claims that Novartis was aware of the possible link to arteriosclerosis as early as 2011, but failed to provide appropriate warnings to doctors and patients. (Case No. No. 16-393)

Tasigna patients who were diagnosed with arteriosclerosis while using this medication, or their surviving family members, may be entitled to compensation for their medical bills, lost wages, pain and suffering, wrongful death, and more. To learn more about filing a Tasigna lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/ 
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP

Related Links

http://www.bernlieb.com